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Rapid intracellular transport and secretion of cytotoxic granules through the immunological synapse requires a balanced interaction of
several proteins. Disturbance of this highly regulated process underlies familial hemophagocytic lymphohistiocytosis (FHL), a genetically
heterogeneous autosomal-recessive disorder characterized by a severe hyperinﬂammatory phenotype. Here, we have assigned FHL-5 to
a 1Mb region on chromosome 19p by using high-resolution SNP genotyping in eight unrelated FHL patients from consanguineous fami-
lies. Subsequently, we found nine different mutations, either truncating or missense, in STXBP2 in twelve patients from Turkey, Saudi
Arabia, and Central Europe. STXBP2 encodes syntaxin binding protein 2 (Munc18-2), involved in the regulation of vesicle transport to
the plasma membrane. We have identiﬁed syntaxin 11, a SNARE protein mutated in FHL-4, as an interaction partner of STXBP2. This
interaction is eliminated by themissensemutations found in our FHL-5 patients, which leads to a decreased stability of both proteins, as
shown in patient lymphocytes. Activity of natural killer and cytotoxic T cells was markedly reduced or absent, as determined by CD107
degranulation. Our ﬁndings thus identify a key role for STXBP2 in lytic granule exocytosis.Introduction
Patients with hemophagocytic lymphohistiocytosis (HLH)
present with episodes of prolonged fever, hepatospleno-
megaly, and cytopenia in at least two lineages associated
with high values of triglycerides and ferritin, an elevated
number of sCD25 molecules, and high IFN-g levels in
the serum. Highly activated natural killer (NK) cells and
cytotoxic T lymphocytes (CTL) show a markedly reduced
or absent killing of (virus-infected) target cells. This high
and lasting stimulation of the immune system is accompa-
nied with an ineffective immune response and may lead to
death unless an adequate immunosuppressive treatment
is begun.1,2 Initial therapeutic strategies always lead to
a marked suppression of the severe hyperinﬂammatory
phenotype, but nevertheless, long-term cure can only be
achieved by stem cell transplantation (SCT) from an alloge-
neic donor. HLH can be aquired or familial; therefore, not
all HLH cases require SCT as an appropriate treatment. Age
at onset, familiarity, and severity of the disease must be
taken into account for the initiation of the transplantation
procedure.
Familialhemophagocytic lymphohistiocytosis (FHL [MIM
267700]) is a rare, autosomal recessively inherited disorder
with a clinical manifestation during infancy in 70%–80%
of the patients.3,4 Previous genetic studies in FHL revealed
an extended genetic heterogeneity. A ﬁrst mapping
approach included four consanguineous families of Pakis-482 The American Journal of Human Genetics 85, 482–492, Octobetani origin and identiﬁed a 7.8 cM region on chromosome
9q21.3-q22, but the underlying defect is still unknown
(FHL-1 [MIM 267700]).5 A second report described linkage
of 10 out of 17 investigated families to a region on chromo-
some 10q21-q22,6 thus indicating genetic heterogeneity.
Mutations in the perforin-1 gene (PRF1 [MIM 170280])
were then described at this locus (FHL-2 [MIM 603553]).7
Twenty to ﬁfty percent of the patients have mutations in
PRF1, with a strong geographical bias in the overall fre-
quency.8–11 Additional genetic defects associated with FHL
affect proteins involved in transport, membrane fusion, or
exocytosis of perforin-containing lytic granules such as
Munc13-4 (MIM 608897; FHL-3 [MIM 608898]) and syn-
taxin 11 (MIM 605014; FHL-4 [MIM 603552]).12,13 Again,
theoverall frequencyofpatientswithaknowngeneticdefect
is strongly associated with their geographical origin. In the
remaining 30%–70% of the familial cases, the genetic basis
of the disease is still unknown.14,15
In order to identify additional candidate genes, we have
screened samples of FHL patients for mutations in PRF1,
UNC13D, or STX11. We identiﬁed 15 unrelated Turkish
and Saudi Arabian patients from consanguineous families
without mutations in any of these genes. After whole-
genome homozygosity mapping in samples from these
patients, we identiﬁedmutations in STXBP2 encoding syn-
taxin binding protein 2 (Munc18-2 [MIM 601717]),
a protein involved in regulation of intracellular trafﬁcking
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Table 1. Summary of Clinical, Laboratory, and Mutation Data of the FHL-5 Patients
Patient Cs Origin Familial
Onset:
Month
of Age
HLH
Criteriaa
HSCT/
Month
of Age
Outcome/
FU (mo) CNS
Cyto-
toxicityb Mutationsc
0870 – German – 28 5/5 no d þ —–/– p.[Leu209Pro]þ[SP]
0879 þ Turkish þ 28 5/5 no e – —/– p.[SP]þ[SP]
0884 þ Turkish – 2 5/5 MMUD/11 NAD/84 þ n.t. p.[Arg292His]þ[Arg292His]
1155 þ Turkish – 2 5/5 no death þ n.t. p.[Ile232 del]þ[Ile232 del]
1875 þ Saudi Arabian þ 4 5/8 MSD n.a. n.a. n.t. p.[Pro477Leu]þ[Pro477Leu]
1945 þ Turkish þ 1.5 5/5 MSD/4.5 NAD/108 þ n.t. p.[Ile232 del]þ[Ile232 del]
1948 þ Turkish – 9 n.a. n.a. n.a. – n.t. p.[Arg405Trp]þ[Arg405Trp]
1949f þ Turkish þ 3 7/8 MUD/6 NAD/20 þ n.t. p.[Arg405Glu]þ[Arg405Glu]
1976-1g þ Saudi Arabian þ 6 5/8 MMUD/12 NAD/23 – —/—– p.[Pro477Leu]þ[Pro477Leu]
1976-2g þ Saudi Arabian þ 1.5 8/8 MUD/3 death of VOD/4 þ —–/— p.[Pro477Leu]þ[Pro477Leu]
2289 – German – 44 4/5 MUD/192 death/144 – —–/– p.[SP]þ[SP]
2290 – German – 15 n.a. MUD/84 death/1.5 n.a. n.t. p.[Leu87ArgfsX32]þ[SP]
2291 – Czech – 15 6/8 MMUD/28 NAD/15 þ n.t. p.[SP]þ[SP]
Abbreviations are as follows: Cs, consanguinity; HSCT, hematopoeitic stem cell transplantation; MMUD, mismatched unrelated donor; MUD, matched unrelated
donor; MSD, matched sibling donor; FU, follow up since diagnosis; NAD, no active disease; VOD veno-occlusive disease; CNS, central nervous system involve-
ment, observed at any time of disease; n.a., not available; n.t., not tested.
a According to Henter et al.16
b NK cells or CTLs; —– indicates absent, — indicates severely reduced, – indicates lower normal range.
c Mutations in STXBP2; SP, splice defect caused by c.1247-1G>C.
d Recurrent reactivations with spontaneous remission or response to steroids.
e Recurrent reactivations responsive to steroids.
f An affected sister (1949-2) showed the same mutation.
g Affected brothers 1976-1, 1976-2.Subjects and Methods
Patients and Diagnosis
All patients included in the study had a proven family background
of hemophagocytic lymphohistiocytosis and/or were diagnosed
according to the diagnostic criteria of the Histiocyte Society.16
Age at onset of the FHL-5 patients ranged from 1.5 mo to 3 yrs
and 8 mo. During the course of the disease, CNS involvement
was observed in seven of the patients. Eleven patients have been
treated according the current protocols (HLH-94 and 2004), and
nine patients have undergone SCT. Familial appearance was re-
ported in ﬁve of our patients on the basis of the presence of
affected siblings. Additional clinical and laboratory data are shown
in Table 1. Some of our FHL patients have been clinically described
before in the literature. Patient 2290 was described by Sparber-
Sauer et al.17 as patient no. 185. A detailed clinical history of
patient 0879 was recently published by our group as pertaining
to patient P12.18 The study was conducted in accordance with
the standards of the Declaration of Helsinki and those of the
participating clinics. All families gave their written informed
consent to the genetic analysis.
Genotyping and Linkage Analysis
DNA was extracted from EDTA blood samples via standard proce-
dures. DNA samples were genotyped with the Affymetrix Gene-
Chip Human Mapping 250K Sty Array (Affymetrix). Genotypes
were called by the GeneChip DNA analysis software (GDAS v3.0,
Affymetrix). Data were checked with the program GraphicalThe AmerRepresentation of Relationships (GRR).19 Parametric linkage anal-
ysis was done with the programs Allegro20 and MERLIN,21
allowing for marker clustering as compensation for linkage
disequilibrium (LD) between adjacent markers. Haplotypes were
constructed with the program Allegro. All data handling was
done with the use of the graphical user interface ALOHOMORA.22
Mutation analysis
PCR products of the coding exons included the adjacent intronic
sequences for identiﬁcation of splice-site variants. Primer
sequences are listed in Table S1, available online. Products were
directly sequenced with BigDye Terminator v1.1 (Applied Biosys-
tems) and run on an ABI PRISM 3100 genetic analyzer.
Quantitative PCR
RNA was either purchased (human tissue total RNA, Clontech) or
isolated from cells obtained by ﬂuorescence-activated cell sorting
(FACS) from human peripheral blood samples via the Trizol (Invi-
trogen) method. One microgram of total RNA was reverse tran-
scribed with the Revert Aid kit (Fermentas) and random hexamers.
The STXBP2 and STX11 transcript levels were determined by rela-
tive quantitative PCR (qPCR). qPCR was performed in a total reac-
tion volume of 24 ml for each well containing 12 ml Platinum SYBR
Green qPCR SuperMix-UDG (Invitrogen), 10ml cDNA 1:50 predi-
luted, and 2 ml primer mix (5 mM each; primer sequences are given
in Table S2). Each sample was analyzed in triplicate and ampliﬁed
on a real-time PCR instrument (Applied Biosystems 7500). Relative
mRNA levels were quantiﬁed via the comparative CT method
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mRNA values were normalized against the average values of
GAPDH, ACTB, 18S rRNA, and TFRC as endogenous controls. For
relative expression analysis, human granulocytes were used as
calibrator.
Immunoﬂuorescence Analysis
For immunoﬂuorescence analysis, FACS-sorted cells from two
independent donors were plated on poly-L-lysine-coated (Sigma)
coverslips in RPMI1640 supplemented with 20% fetal calf serum
(FCS), 2 mM glutamine, and 1 mg/ml Concanavalin A (Sigma) for
30 min. For stimulation, cells were plated after 24 hr on poly-L-
lysine-coated coverslips for 30 min and stimulated with 1 nM
interleukin 2 for 5 min. Cells were ﬁxed in 4% (w/v) paraformalde-
hyde and permeabilized with 0.1% (w/v) saponin. Primary anti-
body labeling was done with anti-STXBP2 (Calbiochem) and
anti-STX11 (BD Biosciences) in 3% (w/v) bovine serum albumin
in PBS (BSA/PBS) for 3 hr at 4C. Coverslips were washed with
13 PBS and incubated with ﬂuorescently labeled secondary anti-
bodies (anti-mouse IgG Alexa 555 and anti-rabbit Alexa 488,
Molecular Probes) in 3% (w/v) BSA/PBS for 1 hr at 4C. Nuclear
DNA was stained with 1 mg/ml DAPI in PBS after secondary anti-
body incubation. Coverslips were washed again with 13 PBS
and mounted on glass slides with Fluoromount G (Electron
Microscopy Sciences). All images were acquired with a Zeiss LSM
510 confocal microscope. Colocalizations were analyzed with
AxioVision software (Zeiss).
NK Cell and T Cell Cytotoxicity and Degranulation
Assays
NK cell cytotoxicity was analyzed in standard 51Chromium-release
assays. In brief, 51Cr-labeled K562 target cells were incubated with
peripheral blood mononuclear cell (PBMC) effectors directly after
Ficoll isolation for 4.5 hr at six different effector-to-target ratios in
96-well U-bottom plates. CTL cytotoxicity was analyzed in a redir-
ected lysis assay. Phytohaemagglutinin (PHA) blasts were cultured
for 6 to 8 days, labeled for 2 hr with anti-CD3 (clone UCHT-1; BD
PharMingen), and used directly as effector cells on 51Cr-labeled
L1210 target cells for 4.5 hr. The amount of 51Cr release into the
supernatant was determined with a Packard Cobra II Auto Gamma
(Perkin-Elmer). NK-to-target and CTL-to-target ratios were calcu-
lated by multiplying the respective effector-to-target-ratio with
the percentage of NK cells and CTLs, respectively, as determined
by ﬂow cytometry.
NK cell degranulation was examined by analyzing the expres-
sion of the lysosomalmarker protein CD107 on activated NK cells.
For this, freshly isolated PBMCs were incubated with K562 cells at
a ratio of 1:1 for 2 hr and then stained with anti-CD3-PerCP, anti-
CD56-PE, anti-NKp46-APC, and anti-CD107a/b-FITC mAbs (all
mAbs were obtained from BD PharMingen). For study of CTL
degranulation, day 2 PHA blasts were stimulated with anti-CD3/
anti-CD28 beads (Dynal Biotech) in the presence of antibodies
against CD107a/b (clones H4A3 and H4B4; BD PharMingen).
Monensin A (Golgistop; BD PharMingen) was added after 1 hr,
and cells were incubated for an additional 4 hr to 5 hr. The cells
were analyzed on a FACScan cytometer with Cellquest Pro soft-
ware (BD Biosciences).
Cloning and Coimmunoprecipitation
Full-length human STXBP2was cloned into the eukaryotic expres-
sion vector pEGFP-C2 (BD Bioscience) with the use of the endonu-
clease restriction sites EcoRI and KpnI, generating an N-terminal484 The American Journal of Human Genetics 85, 482–492, OctobeEnhanced Green Fluorescence Protein (EGFP) fusion protein.
Full-length human STX11 (wild-type [WT]) was cloned in the
expression vector pIRESneo2 (Clontech) as an N-terminal FLAG-
tagged fusion protein.
Generation of STXBP2 Mutants
The STXBP2mutants were generated by use of the QuickChange II
Site-Directed Mutagenesis Kit (Stratagene) in accordance with the
manufacturer’s protocol. Speciﬁc primers containing the respec-
tive mutations were designed by use of the web-based Quick-
Change Primer Design Program.
Expression of EGFP-STXBP2 and FLAG-Syntaxin11
in 293 HEK Cells
Human Embryonic Kidney (HEK) 293 cells were grown in Dulbec-
co’s modiﬁed Eagle’s medium (Invitrogen) containing 10% FCS.
293 HEK cells were cotransfected with EGFP-STXBP2-containing
(WT and mutants) vector and the FLAG-syntaxin11-containing
vector, respectively, with the use of OptiMEM (Invitrogen) and
Lipofectamine 2000 (Invitrogen), in accordance with the manu-
facturer’s protocol. After 48 hr of transfection, EGFP expression
was conﬁrmed by ﬂuorescence microscopy for the determination
of transfection efﬁciency. Cotransfected 293 HEK cells were
washed twice in ice-cold 13 PBS (Invitrogen) and lysed on ice in
lysis buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100 (Sigma Aldrich), and Complete Protease
Inhibitor Cocktail Tablet (Roche). Cell debris were sedimented
by centrifugation (14,000 rpm, 10 min, 4C). Fresh total cell
lysates were directly used for coimmunoprecipitation (Co-IP) anal-
ysis or stored at 4C.
Coimmunoprecipitation Experiments
Protein-G PLUS agarose beads (Santa Cruz Biotechnology) were
preincubated with ANTI-FLAG M2 murine IgG1 monoclonal anti-
body (Sigma Aldrich) in a rotator for 3 hr at 4C. Beads were
washed once with ice-cold 13 PBS before usage. Cotransfected
fresh total 293 HEK cell lysates were diluted in 13 PBS and incu-
bated with anti-FLAG-coupled Protein-G PLUS agarose beads in
a rotator overnight at 4C. Each Co-IP approach was washed
four times with ice-cold 13 PBS followed by elution in 13
Laemmli buffer and boiled for 7 min at 95C for SDS-PAGE
analysis.
SDS-PAGE and Immunoblot Analysis
SDS-PAGE analysis was performed with self-casted SDS gels con-
taining 10% acrylamide at 25mA. Transfer of the proteins to a pol-
yvinylidene ﬂuoride (PVDF) membrane was performed in 10 mM
CAPS buffer, pH 11 containing 10% methanol for 3 hr at 4C,
400 mA. Blotted PVDF membranes were blocked at least 30 min
in 5% dry, nonfat milk solved in 13 TBS. Incubation with the
appropriate primary antibodies (anti-GFP [B2], Santa Cruz
Biotechnology; monoclonal anti-FLAGM2murine and polyclonal
anti-FLAG rabbit, Sigma Aldrich) was performed in 2.5% dry,
nonfat milk solved in 13 TBS over night at 4C. The PVDF
membranes were washed three times in 13 TBS followed by incu-
bation with the appropriate horseradish peroxidase (HRP)-conju-
gated secondary antibodies (purchased from Dako). After three
additional washing steps, the PVDF membranes were incubated
with enhanced chemiluminescence (ECL) (0.1 M Tris-HCl
[pH 8.6], 50 mg Luminol, 11 mg coumaric acid) for 4 min and
exposed on X-ray ﬁlms. For endogenous STXBP2, syntaxin 11,r 9, 2009
and actin detection, cell lysates were run on 4%–12% precast gels
(Invitrogen), transferred onto nitrocellulose, and probed with
rabbit anti-STXBP2 (a gift from V. Olkkonen), raised against
a fragment of canine STXBP2 encoding amino acids 248–593,
which comprise the central and C-terminal parts of STXBP2,23
anti-syntaxin 11 (a gift from R. Prekeris), and mouse anti-actin
(Sigma).
Results
Gene Mapping and Mutation Analysis
In the present study, we have initially screened 48 unre-
lated patients from Turkey (n ¼ 47) or Saudi Arabia (n ¼
1) with a consanguineous family background for muta-
tions in PRF1, UNC13D, or STX11. Eighteen of these
had mutations in PRF1 (38%), seven had mutations in
UNC13D (15%), and eight patients had mutations in
STX11 (17%), thus identifying 15 patients without muta-
tions in any of these genes. With samples of these single
patients, we performed a genome-wide linkage analysis
and homozygosity mapping approach, using chip-based
SNP genotyping. LOD score analysis with the use of
20,000 SNP markers under the assumption of heteroge-
neity and full penetrance revealed a maximum HLOD
score of 5.9 on chromosome 19p (Figure 1A). Reﬁned
calculations with 3700 SNP markers on chromosome 19
gave a heterogeneity LOD (HLOD) score of 8.3 at
rs624968. Detailed genotype analysis identiﬁed an over-
lapping region of homozygosity in seven of the 15
cases (Figure 1B). The remaining eight patients were
heterozygous in this region and were disregarded in the
following investigations. In addition, we included a
previously screened extended consanguineous FHL pedi-
gree from Saudi Arabian origin (1875 in Figure 1C)
comprising two affected and three unaffected siblings
and their parents. Whole-genome analysis of this family
showed three homozygous regions with LOD scores over
2.0. Interestingly, one of these overlapped with the
interval on chromosome 19p found in the analysis of
the single FHL patients. The common region of homozy-
gosity was 1040 kb in length and contained 36 genes
(Figure 1C).
In a search for potential candidate genes, we focused on
genes with a potential role in immune cells, the most
promising of which was STXBP2. By direct sequencing,
we then identiﬁed mutations in STXBP2 in all eight
patients who mapped to the critical region (Figure 2A,
Table 1, and Table 2). The gene encompasses 19 exons
and codes for syntaxin binding protein 2, also known as
Munc18-2, consisting of 593 amino acids. When screening
other patients from nonconsanguineous FHL families, we
identiﬁedmutations in STXBP2 in four additional patients,
three from Germany and one from the Czech Republic
(Table 1). In total, we identiﬁed ﬁve different missense
mutations, one 3 bp deletion, two frameshift deletions,
and a mutation at position 1 (c.1247-1G>C) of the splice
acceptor site of exon 15 (Figure 2A and Table 2). In patientThe Amer0879, homozygous for the splice-site mutation, analysis of
RNA revealed a deletion of exon 15 resulting in a frameshift
and 126 new codons as amajor event (p.Val417LeufsX126)
but also a variety of other, including in-frame, products
(Figure S1).
All missense mutations affect amino acids that are
highly conserved among 40 proteins of the Sec/Munc
family of syntaxin binding proteins from various species.
This was also demonstrated by the ConSeq score that
goes up to 9 for the highest degree of conservation (Table
2).24 Interestingly, we found the same homozygous muta-
tion in the two Saudi Arabian patients. However, analysis
of microsatellites and SNPs around STXBP2 did not show
a conserved haplotype, excluding at least a closer relation-
ship between the patients. Corresponding heterozygous
mutations were detected in all of the parents, where avail-
able, but not in 210 chromosomes from ethnically
matched control persons. We identiﬁed homozygous
missense mutations in 5 out of 12 patients and a 3 bp dele-
tion (c.693_695delGAT) in 2 of the 12 patients. These
seven patients had early-onset disease ﬁrst diagnosed
before one year of age. The remaining ﬁve patients devel-
oped HLH after the ﬁrst year of life. These patients either
had a homozygous splice site mutation (c.1247-1G>C)
or were compound heterozygous for two mutations,
including the splice-site mutation.
Protein Stability
In order to determine the pathophysiologic relevance of
different STXBP2 mutations, we generated T cell clones
and/or PHA blasts from ﬁve patients. In cell lysates from
patients with a homozygous missense mutation (1976-1,
1976-2), we found reduced amounts of STXBP2 in an
immunoblot analysis (Figure 2B). In patients with a homo-
zygous splice-site mutation (patients 0879 and 2289),
slightly different signals of approximately the correct size
were detected. Remarkably, we also observed markedly
decreased levels of syntaxin 11 in the patients with a
homozygous missense mutation in STXBP2 but not in
patients with the homozygous splice-site mutation (Fig-
ure 2B). One patient with compound heterozygosity for
a splice site and a missense mutation (0870) demonstrated
an intermediate amount of syntaxin 11.
Protein Interaction Studies and Cellular Localization
To further corroborate the importance of the missense
mutations, we then searched for potential interaction part-
ners of STXBP2. Given that STXBP2 has previously been
shown to interact with syntaxins 2 and 3 in epithelial
and mast cells, we speculated that in CTL and NK cells,
interactions between STXBP2 and syntaxin 11 could be
important for cytotoxic granule release. By Co-IP, we
demonstrated that STXBP2 and syntaxin 11 share com-
mon binding sites (Figure 2C). Using site-directed muta-
genesis, we showed that all of the identiﬁed missense
mutations in STXBP2 lead to a complete loss of the ability
to bind to syntaxin 11 (Figure 2C). As expected, loss ofican Journal of Human Genetics 85, 482–492, October 9, 2009 485
Figure 1. Identification of Mutations in STXBP2 Underlying FHL Type 5
(A) A genome-wide linkage scanwas performed in 15 single patients with FHL from consanguineous families. LOD scores assuming locus
heterogeneity (HLOD scores) were plotted for all autosomes, corresponding to approximately 3500 cM in total length, and revealed
a locus on chromosome 19 with a maximum LOD score of 5.9.
(B) SNP genotypes of seven FHL patients with homozygosity around STXBP2. Names of markers and their genetic localization are shown
on the left. STXBP2 is located between rs4804217 and rs12610253.
(C) Eight patients showed overlapping regions of homozygosity on chromosome 19 (horizontal boxes). The minimal region (vertical
box) was 1 Mb in length and contained the gene STXBP2. Pedigree 1875 (asterisk) was mapped independently and is not included in
the LOD score analysis summarized in (A).486 The American Journal of Human Genetics 85, 482–492, October 9, 2009
binding to syntaxin 11 was not observed when STXBP2
was used with a polymorphic variant in a little conserved
residue, p.Ala433Val (not shown).
Real-time quantitative PCR data revealed a high degree
of correlation between the expression of STXBP2 and
STX11 in different hematopoietic cells (Figure 3). Consis-
tent with the supposed pathophysiology of FHL, a particu-
larly high expression was observed in NK cells, monocytes,
and T cells. Moreover, we have demonstrated colocaliza-
tion of STXBP2 and syntaxin 11 in CD8þ T and NK cells
via immunoﬂuorescence analysis (Figure S2), which was
weak only in B cells. Stimulation with interleukin 2 (IL-2)
further enhanced the colocalization in CD8þ and NK cells.
Taken together, these data suggest that syntaxin 11 is stabi-
lized through a STXBP2/syntaxin 11 interaction, which is
impaired in FHL-5 patients with a missense mutation in
STXBP2.
Cytotoxicity and Degranulation
Recent ﬁndings have shown that patients with either FHL-
3 or FHL-4 show a marked impairment of their capacity to
Figure 2. Structure of STXBP2, Protein
Stability, and Interaction
(A) STXBP2 consists of 19 exons and
includes 593 codons (dark gray). It encodes
syntaxin binding protein 2 (STXBP2),
which contains a large Sec1 domain (light
gray). We identiﬁed nine different muta-
tions distributed throughout the gene. SP,
splice mutation c.1247-1G>C.
(B) Lysates from PHA blasts obtained
from FHL-5 patients and control persons
were analyzed for presence of STXBP2
and syntaxin 11. Patients showed reduced
amounts of STXBP2. Moreover, patients
with the homozygous STXBP2 missense
mutation p.Pro477Leu (1976-1, 1976-2)
showed clearly decreased amounts of syn-
taxin 11. Patient 0870, compound hetero-
zygous for the splice-site mutation
c.1247-1G>C and the missense mutation
p.Leu209Pro, revealed an intermediate
pattern.
(C)Coimmunoprecipitationdemonstrated
shared binding sites between STXBP2 and
syntaxin 11. The ability to bind to syntaxin
11 is lost in all STXBP2 mutants with
missense mutations and the one-codon
deletion identiﬁed in our patients with
FHL-5 (upper panel). All of the STXBP2
mutants were evenly detectable (lower
panel).
secrete cytotoxic granules of either
NK cells or T cells to their cell surface
because of defective Munc13-4 and
syntaxin 11, respectively.25,26 This
ﬁnding also discriminates between
patients with FHL-2 and FHL types 3
and 4. In order to assess the cytotoxic
capacities in FHL-5 cases and assign
them to a disease category, we analyzed degranulation
and cytotoxicity of NK cells and CTLs in two early-onset
and three late-onset patients with STXBP2 mutations. We
measured NK cell and T cell degranulation after stimula-
tion of intracellular granule exocytosis by extracellular
staining of CD107 in four patients. CD107 was absent in
three of the patients and in the lower normal range in
one late-onset patient (Figure 4A). Ex vivo cytotoxicity
on NK cell-sensitive K562 targets was impaired in all ﬁve
patients tested, but one early-onset and one late-onset
patient showed residual activity (Figure 4A). CTL degranu-
lation was low in PHA blasts from all patients analyzed
(Figure 4B). Additionally, CTL cytotoxicity was very low
in two early-onset patients but in the lower normal range
in three late-onset patients (Figure 4B). Similar to what is
observed in patients with syntaxin-11 deﬁciency, the
degranulation (not shown) and cytotoxicity defects could
be at least partially reversed after in vitro stimulation
with IL-2, indicating the activation of yet-undeﬁned syn-
taxin-11/STXBP2 independent pathways under these
conditions (Figure 4C).The American Journal of Human Genetics 85, 482–492, October 9, 2009 487
Table 2. Summary of Mutations Identified in STXBP2 in Patients with FHL
Mutation Exon Protein ConSeqa Patient Genotypeb
c.260delT 5 p.Leu87ArgfsX32 – 2290 comp het
c.626T>C 8 p.Leu209Pro 5 0870 comp het
c.693_695delGAT 9 p.Ile232del 8 1155 homo
1945 homo
c.706delG 9 p.Ala236GlnfsX24 – 2291 comp het
c.875G>A 10 p.Arg292His 8 0884 homo
c.1213C>T 14 p.Arg405Trp 9 1948 homo
c.1214G>A 14 p.Arg405Glu 9 1949d homo
c.1247-1G>Cc 15 p.Val417LeufsX126c – 0879 homo
2290 comp het
0870 comp het
2291 comp het
2289 homo
c.1430C>T 16 p.Pro477Leu 7 1976e homo
1875 homo
a The score for the evolutionary conservation of amino acids24 is included for residues changed as a result of missense mutations. The score is between grades 1
(variable) and 9 (conserved).
b Abbreviations are as follows: homo, homozygous; comp het, compound heterozygous.
c Splice mutation; only the major consequence is included. See text for details.
d An affected sister (1949-2) showed the same mutation.
e An affected brother (1976-2) showed the same mutation.Discussion
Fast secretory granule exocytosis is often mediated by
SNARE (soluble N-ethylmaleimide sensitive factor attach-
ment protein [SNAP] receptor) complexes and represents
a fundamental process for the release of neurotransmitter
molecules in the neuronal system and for secretory lyso-
somes in immune cells.27,28 The analysis of genetic disor-
ders characterized by defects in membrane trafﬁcking in
immune cells, particularly in patients with FHL, has488 The American Journal of Human Genetics 85, 482–492, Octoberdecisively contributed to unravelling the secretion
machinery.29–31 Here, we report that FHL type 5 (FHL-5)
is caused by missense and truncating mutations in
STXBP2. We used FHL patients from consanguineous fami-
lies of Turkish and Saudi Arabian descent to search for
unknown loci via autozygosity mapping. Because larger
pedigrees with FHL patients are particularly rare, we col-
lected samples of single cases for genome-wide screening,
assuming that several of these would share a common
region of homozygosity and that patients from the sameFigure 3. Expression of STXBP2 and
STX11
Relative quantiﬁcation of STXBP2 and
STX11 in various human tissues by real-
time PCR. Expression of both STXBP2
and STX11 is similar and particularly
high in NK cells, T cells, monocytes, and
other hematopoietic cells. Quantiﬁcation
was done with the use of ACTB, GAPDH,
TFRC, and 18S rRNA as references5 SD.9, 2009
Figure 4. NK and T Cell Degranulation
and Cytotoxicity of Patients with Muta-
tions in STXBP2
(A and B) NK cell degranulation was exam-
ined by ﬂow cytometry with the use of
antibodies against CD107 after stimula-
tion of PBMC with K562 cells (A). Plots
are gated on CD3 NKp46þ cells (left
panel). CTL degranulation was examined
by ﬂow cytometry with the use of anti-
bodies against CD107 after stimulation
with anti-CD3/anti-CD28 microbeads (B).
Plots are gated on CD3þ cells. The middle
panels show the percentage of CD107þ
expression on stimulated NK cells and
CTLs, respectively, of patients and 30
healthy controls (box, mean and 25%–
75% percentile; whiskers, maximum and
minimum value observed). The right
panels show NK cell cytotoxicity against
K562 target cells and CTL cytotoxicity
against L1210 target cells, respectively.
The shaded areas indicate the mean
percentage of target cell lysis 5 two stan-
dard deviations of 30 healthy controls.
The NK:target and CTL:target ratios were
determined by ﬂow cytometry.
(C) Reconstitution of NK cell cytotoxicity
after in vitro stimulation with IL-2. Left
panel: Cytotoxicity of PBMC of patient
1976-2 and a healthy control person were
assessed against K562 target cells. The NK
cell to target ratio was determined by
ﬂow cytometry. Right panel: PBMC were
cultured for 7 days in medium supple-
mented with 100 U/ml recombinant IL-2
before analysis of cytotoxicity on K562
target cells.area might exhibit a common founder haplotype. High-
resolution chip-based SNP analysis did in fact allow us to
identify a candidate region on chromosome 19p13 in 7
out of 15 patients with FHL and then led to the identiﬁca-
tion of mutations in STXBP2, the strongest functional
candidate in this region.
In total, we detected nine different homozygous or
compound heterozygous mutations in twelve indepen-
dent patients of different geographic origins. We identiﬁed
ﬁve missense mutations affecting highly conserved resi-
dues, one in-frame and two frameshift deletions, as well
as a mutation at the splice acceptor site of exon 15. All of
the mutations scattered over the whole gene. Although
six of the patients descended from consanguineous
Turkish and two from consanguineous Saudi Arabian fami-
lies, we found the identical homozygousmutations only in
two Turkish and in the two Saudi Arabian families, respec-
tively. Marker analysis around STXBP2 excluded a founder
mutation even in these families, further indicating allelic
heterogeneity in FHL-5. FHL-5 is therefore neither
restricted to any distinct ethnic or geographic origin, as is
the case in FHL-4, nor caused by a hotspot mutation in
STXBP2, such as mutation p.Trp374X in PRF1 in Turkish
patients with FHL-2.14,15,32 This is underlined by our obser-
vation of mutations in STXBP2 in four FHL patients fromThe AmerCentral Europe as well. Nevertheless, the exact frequency
of FHL-5 has yet to be evaluated in a larger group of FHL
patients.
The exact function of STXBP2 within the secretory
machinery of immune cells is still not well understood.
From previous studies, it is known that STXBP2 is impor-
tant for controlling intracellular granule/membrane traf-
ﬁcking in polarized epithelial cells, neutrophils, and mast
cells.33–36 Our expression studies conﬁrmed this pattern
and also demonstrated strong signals in other hematopoi-
etic cells, such as T cells, NK cells, and monocytes. Interest-
ingly, this expression is very similar to the expression of
STX11, which has been shown before in various hemato-
poietic cells,25,37,38 and STXBP2 and syntaxin 11 colocalize
in CD8þ Tcells and NK cells. The increase in colocalization
after stimulation with IL-2 is in line with the enhanced
cytotoxic activity of NK cells induced by IL-2.39 STXBP2
appears in a granule-like pattern, as observed in mast
cells, where it is redistributed into forming lamellipodia
upon stimulation.34 Using coimmunoprecipitation experi-
ments, we have demonstrated a direct interaction of
STXBP2 with syntaxin 11. STXBP2 belongs to the Sec/
Munc family of regulatory proteins involved in the
assembly and disassembly of SNARE complexes and con-
trol of the speciﬁcity and timing of membrane fusion.ican Journal of Human Genetics 85, 482–492, October 9, 2009 489
Syntaxin 11 is an atypical member of the Q subfamily of
SNARE proteins40 and is mutated in FHL-4.13 It has been
reported that an interaction with syntaxin 3, another
SNARE protein, could be disturbed by introducing
missense mutations into STXBP2.33,35 One of these,
p.Arg405Pro, which corresponds to the yeast mutant
sec1-11, showed an almost complete loss of association
with syntaxin 3, as observed with the use of in vitro and
in vivo assays.33 The same highly conserved residue was
mutated in two of our patients (patient 1948, p.Arg405Trp;
patient 1949, p.Arg405Glu) and led to the loss of interac-
tion with syntaxin 11. Experiments in mast cell lines also
showed the importance of STXBP2 in granule exocytosis
of these cells.34 Moreover, an interaction of STXBP2 and
syntaxin 3 and a role for STXBP2 in granule exocytosis
were recently shown in neutrophils.36 STXBP2 can thus
contribute to the granule exocytosis machinery through
the interaction with various SNARE proteins in different
cell types.
If functional STXBP2 is absent as a result of missense
mutations, syntaxin 11 seems to be destabilized. This indi-
cates an interaction between the proteins and suggests
a STXBP2/syntaxin-11 complex essential for protein
stability. A similar effect was recently observed for com-
plexes of Rab27a, which is mutated in patients with Gris-
celli syndrome type 2 (GS-2),41 with Slp1 and Slp2-a,
respectively.42 Interestingly, GS-2 patients also develop
HLH symptoms during the course of their disease. In con-
trast, syntaxin 11 appears to be present in normal amounts
in patients with the homozygous splice-site mutation
c.1247-1G>C in STXBP2. This may indicate a ‘‘leaky’’
splice mutation. Moreover, the cDNA analysis in one
patient revealed the loss of exon 15 as a major event,
which gives rise to a frameshift after codon 416 and
a potential protein of almost the same size as STXBP2
and several other products. It is possible that some of these
products, as detected in the immunoblot analysis, are
effective for stabilization of syntaxin 11 and lead to the
milder defect in CTL cytotoxicity observed here and the
later onset of the disease in comparison to the severe cases
with STXBP2 missense mutations.
The pronounced and sustained immune dysregulation
in FHL is caused mainly by defects in cellular cytotoxicity,
which is required not only for pathogen control but also
for immune homeostasis. In the absence of a negative feed-
back signal, continuous stimulation of T cells and subse-
quent activation of macrophages lead to the characteristic
hypercytokinemia and fatal organ inﬁltrations.29,43 Muta-
tions in PRF1 (FHL-2), UNC13D (FHL-3), and STX11 (FHL-
4) all affect this secretory pathway of NK cells and T cells,
either through an inactivation of the granule content (per-
forin 1) or by impairing the delivery of such granules
through the plasma membrane, caused by defects in
Munc13-4 or syntaxin 11. Finally, target cells are recog-
nized appropriately but not killed effectively, ending in
the severe clinical picture of a hemophagocytic syndrome.
Functional tests in NK cells and CTLs from our FHL-5490 The American Journal of Human Genetics 85, 482–492, Octobepatients underline these ﬁndings. We showed a severe
reduction of both the degranulation capacity and the
capacity to kill target cells. Interestingly, the latter defect
can be partially restored by short-term culturing with
IL-2. Given that IL-2 upregulates the expression of perforin
and granzymes44,45 and that the partial restoration of
degranulation and cytotoxicity by NK cells was already
described for patients with FHL-425 but was not seen in
patients with FHL-3, we assume that the increase in
protein production may allow secretion of these proteins
via alternative routes that bypass the defective STXBP2/
syntaxin-11 pathway.
In themajority of our FHL-5 patients, we foundmissense
mutations in STXBP2 affecting highly conserved residues.
This observation is somewhat surprising in comparison to
the other FHL-related genes, in which the majority of
mutations lead to a premature stop of the protein syn-
thesis.46,47 This may underline the importance of STXBP2
in granule exocytosis. Interestingly, missense mutations
also dominate in early infantile epileptic encephalopathy
type 4 (MIM 612164), which is caused by mutations in
STXBP1 (Munc18-1), the neuronal homolog of STXBP2.48
STXBP1 plays a major role in secretory vesicle release
through the control of SNARE complex formation, and
the protein itself seems to act as a ‘‘chief commander’’ to
make exocytosis more efﬁcent.27,49 However, the role of
STXBP2 and its interaction with syntaxin 11 in lympho-
cyte cytotoxicity that have been elucidated by our ﬁndings
in FHL-5 are proof of the crucial relevance of STXBP2
for intracellular vesicle trafﬁcking and lytic granule exocy-
tosis.
Supplemental Data
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